180 related articles for article (PubMed ID: 26937756)
1. Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Friedlander ML; Russell K; Millis S; Gatalica Z; Bender R; Voss A
Int J Gynecol Cancer; 2016 May; 26(4):648-54. PubMed ID: 26937756
[TBL] [Abstract][Full Text] [Related]
2. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
3. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
4. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Howitt BE; Strickland KC; Sholl LM; Rodig S; Ritterhouse LL; Chowdhury D; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncoimmunology; 2017; 6(2):e1277308. PubMed ID: 28344892
[TBL] [Abstract][Full Text] [Related]
5. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
6. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.
Bolton KL; Chen D; Corona de la Fuente R; Fu Z; Murali R; Köbel M; Tazi Y; Cunningham JM; Chan ICC; Wiley BJ; Moukarzel LA; Winham SJ; Armasu SM; Lester J; Elishaev E; Laslavic A; Kennedy CJ; Piskorz A; Sekowska M; Brand AH; Chiew YE; Pharoah P; Elias KM; Drapkin R; Churchman M; Gourley C; DeFazio A; Karlan B; Brenton JD; Weigelt B; Anglesio MS; Huntsman D; Gayther S; Konner J; Modugno F; Lawrenson K; Goode EL; Papaemmanuil E
Clin Cancer Res; 2022 Nov; 28(22):4947-4956. PubMed ID: 35816189
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
9. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
10. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
12. Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.
Baniak N; Fadare O; Köbel M; DeCoteau J; Parkash V; Hecht JL; Hanley KZ; Gwin K; Zheng W; Quick CM; Jarboe EA; Liang SX; Kinloch M
Am J Surg Pathol; 2019 Apr; 43(4):531-537. PubMed ID: 30585826
[TBL] [Abstract][Full Text] [Related]
13. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
[TBL] [Abstract][Full Text] [Related]
14. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
Valtcheva N; Lang FM; Noske A; Samartzis EP; Schmidt AM; Bellini E; Fink D; Moch H; Rechsteiner M; Dedes KJ; Wild PJ
BMC Cancer; 2017 Jan; 17(1):66. PubMed ID: 28103826
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of clear cell adenocarcinoma of the urinary tract.
Lin CY; Saleem A; Stehr H; Zehnder JL; Pinsky BA; Kunder CA
Virchows Arch; 2019 Dec; 475(6):727-734. PubMed ID: 31372739
[TBL] [Abstract][Full Text] [Related]
16. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Joneja U; Vranic S; Swensen J; Feldman R; Chen W; Kimbrough J; Xiao N; Reddy S; Palazzo J; Gatalica Z
J Clin Pathol; 2017 Mar; 70(3):255-259. PubMed ID: 27531819
[TBL] [Abstract][Full Text] [Related]
18. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
[TBL] [Abstract][Full Text] [Related]
19. Clear cell odontogenic carcinomas show EWSR1 rearrangements: a novel finding and a biological link to salivary clear cell carcinomas.
Bilodeau EA; Weinreb I; Antonescu CR; Zhang L; Dacic S; Muller S; Barker B; Seethala RR
Am J Surg Pathol; 2013 Jul; 37(7):1001-5. PubMed ID: 23715163
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
